OPEN ACCESS Freely available online

ISSN: 2161-1459
Journal of Clinical & Experimental Pharmacology

Short Communication

Overcoming Main Challenges in Macrophage-Mediated Drug Delivery

Ying Chen*

Laboratory of Drug Delivery, School of Medicine, Shanghai University, Shanghai, China

DESCRIPTION

Macrophages, as versatile immune cells, have achieved significant interest in the field of drug delivery. Their inherent ability to home to sites of inflammation, infection, and tumors makes them potential carriers for therapeutic agents. However, utilizing macrophages for drug delivery is fraught with numerous challenges across each step of the process. From isolation and loading of drugs to targeting, release, and overcoming biological barriers, each stage presents unique obstacles that must be addressed to control the full potential of macrophage-based therapies.

Isolation and cultivation of macrophages

The initial step in macrophage-mediated drug delivery is the isolation and cultivation of these cells. Obtaining a sufficient quantity of macrophages from patients or donors is challenging due to their relatively low abundance in peripheral blood. Furthermore, ensuring the purity and viability of isolated macrophages is important, as contaminating cells can affect the efficacy and safety of the therapy. Culturing macrophages *ex vivo* also presents difficulties, as they can undergo phenotypic changes and lose their native functions outside the body. Maintaining their functional integrity during expansion is essential to preserve their therapeutic potential [1,2].

Drug loading efficiency and stability

Loading macrophages with therapeutic agents efficiently is another significant hurdle. The drug must be encapsulated, adsorbed, or chemically conjugated to the macrophages without affecting their viability and function. Achieving a high drug loading efficiency while ensuring that the drug remains stable and active within the macrophage is important. Some drugs may be toxic to macrophages at higher concentrations, posing a risk to cell viability. Additionally, the drug-loading process should not induce unintended activation or differentiation of the macrophages, which could alter their behavior and therapeutic efficacy [3,4].

Targeting and homing to disease sites

One of the primary advantages of using macrophages for drug delivery is their natural ability to home to sites of inflammation and tumors. However, directing macrophages specifically to the desired target site remains a significant challenge. While macrophages inherently migrate to certain pathological areas, achieving precise targeting can be difficult. The heterogeneity of disease sites, variations in the inflammatory microenvironment, and competition with endogenous macrophages can all affect the efficiency of targeted delivery. Strategies such as genetic engineering or surface modification of macrophages are being explored to enhance their targeting capabilities [5,6].

Overcoming biological barriers

Macrophages used as drug carriers must navigate various biological barriers to reach their target. The vascular endothelium, extracellular matrix, and immune surveillance mechanisms can impede the efficient trafficking of macrophages. For instance, macrophages must traverse the endothelial lining of blood vessels to infiltrate tumors or inflamed tissues. This transmigration process can be hindered by the dense extracellular matrix or the presence of other immune cells. Furthermore, macrophages may be recognized and cleared by the host's immune system, particularly in cases where allogeneic or xenogeneic cells are used. Strategies to enhance the migration and infiltration of macrophages while evading immune detection are important for effective drug delivery [7,8].

Controlled release of therapeutics

Ensuring controlled and sustained release of the therapeutic agent at the target site is essential for the success of macrophage-mediated drug delivery. Macrophages can phagocytose and sequester drugs, but releasing them in a controlled manner can be challenging. The release profile should be customized to maintain therapeutic concentrations of the drug over the required duration. Factors such as the nature of the drug, its formulation, and the intracellular environment of the

Correspondence to: Ying Chen, Laboratory of Drug Delivery, School of Medicine, Shanghai University, Shanghai, China, E-mail: chenyy3342@qq.com

Received: 06-May-2024; Manuscript No. CPECR-24-26371; **Editor assigned:** 08-May-2024; PreQC. No. CPECR-24-26371 (PQ); **Reviewed:** 22-May-2024; QC. No. CPECR-24-26371; **Revised:** 29-May-2024; Manuscript No. CPECR-24-26371 (R); **Published:** 06-Jun-2024, DOI: 10.35248/2161-1459.24.14.423

Citation: Chen Y (2024) Overcoming Main Challenges in Macrophage-Mediated Drug Delivery. J Clin Exp Pharmacol. 14:423.

macrophage influence the release kinetics. Designing drug formulations that respond to specific stimuli in the target microenvironment, such as pH or enzymatic activity, can aid in achieving controlled release [9,10].

Monitoring and evaluating therapeutic efficacy

Once macrophages loaded with therapeutics reach the target site, monitoring their distribution, activity, and therapeutic efficacy is vital. Traditional imaging techniques may not provide the resolution or specificity required to track macrophages accurately *in vivo*. Advanced imaging modalities, such as Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET), along with the use of labeled macrophages, can enhance tracking capabilities. Evaluating the therapeutic outcomes also necessitates strong biomarkers and assays to assess the impact of the treatment on the disease progression and the host's immune response.

CONCLUSION

The use of macrophages for drug delivery holds potential due to their unique properties and natural homing abilities. However, realizing their full potential involves overcoming significant challenges at each stage of the process. From efficient isolation and drug loading to precise targeting, navigating biological barriers, ensuring controlled release, and monitoring therapeutic outcomes, each step demands careful optimization and innovation. Addressing these challenges through interdisciplinary research and technological advancements will prepare for effective macrophage-mediated therapies, suggesting new methods for treating a variety of diseases.

REFERENCES

1. Bennett B. Isolation and cultivation in vitro of macrophages from various sources in the mouse. Am J Pathol. 1966;48(1):165.
2. Cohen AB, Cline MJ. The human alveolar macrophage: Isolation, cultivation in vitro, and studies of morphologic and functional characteristics. J Clin Invest. 1971;50(7):1390-1398.
3. Kim S, Shi Y, Kim JY, Park K, Cheng JX. Overcoming the barriers in micellar drug delivery: Loading efficiency, *in vivo* stability, and micelle–cell interaction. Expert Opin Drug Deliv. 2010;7(1):49-62.
4. Leonetti B, Perin A, Ambrosi EK, Sponchia G, Sgarbossa P, Castellin A, et al. Mesoporous zirconia nanoparticles as drug delivery systems: Drug loading, stability and release. J Drug Deliv Sci Technol. 2021;61:102189.
5. Ta HT, Prabhu S, Leitner E, Jia F, von Elverfeldt D, Jackson KE, et al. Enzymatic single-chain antibody tagging: A universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ Res. 2011;109(4):365-373.
6. Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol (Camb). 2010;2(7-8):326-337.
7. Liang T, Zhang R, Liu X, Ding Q, Wu S, Li C, et al. Recent advances in macrophage-mediated drug delivery systems. Int J Nanomedicine. 2021:2703-2714.
8. Wang HF, Liu Y, Yang G, Zhao CX. Macrophage-mediated cancer drug delivery. Mater Today Sustain. 2021;11:100055.
9. Garash R, Bajpai A, Marcinkiewicz BM, Spiller KL. Drug delivery strategies to control macrophages for tissue repair and regeneration. Exp Biol Med (Maywood). 2016;241(10):1054-1063.
10. Nguyen VD, Min HK, Kim DH, Kim CS, Han J, Park JO, Choi E. Macrophage-mediated delivery of multifunctional nanotherapeutics for synergistic chemo–photothermal therapy of solid tumors. ACS Appl Mater Interfaces. 2020;12(9):10130-10141.